STONY BROOK, N.Y., Oct. 11 /PRNewswire/ -- Stony Brook-based Viatronix Incorporated is pleased to announce the publication of another independent study conducted by Perry J. Pickhardt et al. at the University of Wisconsin titled “Screening for Colorectal Neoplasia with CT Colonography” published online in September 2006 in Radiology. This is the result of a one year, third-party payer-reimbursed program at University of Wisconsin, conducted exclusively on the commercially available version of the Viatronix V3D-Colon Platform.
In short, the study once again proves that the Viatronix Virtual Colonoscopy system used in routine clinical practice has proven to be successful in mainstream medicine.
“After the landmark multi-center clinical trial -- published in December 2003 in the New England Journal of Medicine, exclusively using the Viatronix V3D-Colon platform that proved the sensitivity and specificity of the Viatronix virtual colonoscopy to be equal to or better than optical colonoscopy for colon cancer screening, this study is important in that it further demonstrates the clinical efficacy of the Viatronix V3D-Colon platform in a normal day-to-day clinical setting,” said Zaffar Hayat, President of Viatronix.
“All the virtual colonoscopy studies were read on the commercially available version of the Viatronix V3D-Colon platform that accelerates primary 3D evaluation with 2D problem solving. As a result of the improvement in the software, the radiologists were able to interpret the studies in 10 minutes or less,” he went on to say.
“The program initiated at the University of Wisconsin is the first in the nation to have received standard third-party coverage for CTC. The procedure is gaining demand by word of mouth both from the public as well as from referring physicians,” said Dr. Perry Pickhardt.
Colorectal cancer remains the second leading cause of colon cancer deaths in the United States. The need for an effective screening option in the US is reflected by the fact that an estimated 60% of the intended population has not been screened. With proper screening 95% of colon cancers would be preventable.
“The results of the study prove that combining start-of-the-art (Viatronix) 3D CTC examination with an existing OC practice can be a viable and generalizable means towards achieving the goal of detection and removal of large polyps in the majority of the screening population. Using a primary 3D approach proved much more successful than using primary 2D evaluation, which lacks the benefit of 3D polyp detection,” said Dr. Pickhardt.
The authors of the study strongly feel that the results of this study can be easily replicated at other sites by following the approach of the University of Wisconsin team of physicians. Dr. Pickhardt and colleagues lead several hands-on training courses throughout the year to teach their technique to others. Also, the results of the study prove that CT Colonography complements rather than displaces optical colonoscopy. The data from this study also proves its cost effectiveness.
About Viatronix
Viatronix is a leading innovator and developer of 2D/3D medical imaging and diagnostic software. Our software enables physicians to interactively view vital organs and anatomical structures within the human body from data acquired by standard medical imaging equipment in minimally or non-invasive methods. The 2D digital data acquired from imaging devices is automatically post processed using the company’s proprietary software techniques and provides 3D diagnostic quality images for the physician. The company’s first product, V3D-Colon for “virtual colonoscopy” allows physicians to interactively view the colon reconstructed from a CT scan, providing visualization of the inner surface that includes polyps and lesions. The company’s V3D-Explorer offers a robust and user-friendly workstation platform that views and reconstructs data in 2D/3D for virtually any organ in the body. V3D-Calcium Scoring aids physicians in determining the amount of calcified plaque accumulation in the coronary arteries. V3D-Vascular is breakthrough software that permits rapid segmentation and visualization of complex arterial structures using 3D volume rendering, maximum intensity projection and simulated x-ray views. Viatronix, through application of the V3D technology, is developing additional innovative products that will be useful in early detection of other diseases, treatment planning, intervention and follow up evaluation. Viatronix, Inc. is located in Stony Brook, NY. For further information, call toll free 1-866-887-4636 or log on to: www.viatronix.com
Viatronix Incorporated
CONTACT: Susan Levin of Viatronix Inc., +1-631-444-9700,Susan_PR@viatronix.com
Web site: http://www.viatronix.com/
